Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.
Voluntarily sign the informed consent form.
Seasonal allergic rhinitis has been prevalent for at least 2 years.
Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.
Positive serum-specific IgE test results.
Other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination.
Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.
Subjects with poorly controlled recent asthma conditions.
Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.
Parallel
GR1802 injection
Biological/VaccineRecombinant fully human anti-IL4Rα monoclonal antibody drug.
Placebo
Biological/VaccinePlacebo
Change from Baseline in rTNSS( reflective total nasal symptom scores)
Scores range from 0 to 12, with higher scores indicating more severe symptoms.
Change from Baseline in rTOSS( reflective total ocular symptom scores)
Scores range from 0 to 9, with higher scores indicating more severe symptoms.
Change from Baseline in rTNSS
Scores range from 0 to 12, with higher scores indicating more severe symptoms.
Mean change from baseline in iTNSS(instantaneous total nasal symptom scores)
Scores range from 0 to 12, with higher scores indicating more severe symptoms.
Mean change from baseline in iTOSS(instantaneous total ocular symptom scores)
Scores range from 0 to 9, with higher scores indicating more severe symptoms.
Click on the lead sponsor to view all of their trials.
